Compass Therapeutics (CMPX) Expected to Announce Quarterly Earnings on Thursday

Compass Therapeutics (NASDAQ:CMPX) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Compass Therapeutics to post earnings of ($0.10) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Compass Therapeutics Stock Up 1.3%

NASDAQ CMPX opened at $6.47 on Thursday. Compass Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $6.88. The business has a 50 day moving average price of $5.74 and a two-hundred day moving average price of $4.57. The stock has a market cap of $1.15 billion, a PE ratio of -14.38 and a beta of 1.46.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. LPL Financial LLC raised its position in shares of Compass Therapeutics by 4.7% during the 4th quarter. LPL Financial LLC now owns 44,470 shares of the company’s stock valued at $239,000 after acquiring an additional 2,000 shares in the last quarter. Victory Capital Management Inc. increased its stake in Compass Therapeutics by 20.6% during the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock valued at $44,000 after purchasing an additional 2,164 shares during the last quarter. Focus Partners Wealth raised its holdings in shares of Compass Therapeutics by 16.2% during the third quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock worth $56,000 after purchasing an additional 2,206 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Compass Therapeutics by 1.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company’s stock worth $619,000 after buying an additional 3,329 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Compass Therapeutics by 48.5% in the 4th quarter. Russell Investments Group Ltd. now owns 11,558 shares of the company’s stock worth $62,000 after buying an additional 3,773 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on CMPX shares. Craig Hallum started coverage on shares of Compass Therapeutics in a report on Friday, February 13th. They set a “buy” rating and a $15.00 price target for the company. Wall Street Zen raised shares of Compass Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Raymond James Financial reaffirmed an “outperform” rating and set a $9.00 target price on shares of Compass Therapeutics in a research report on Tuesday, January 6th. D. Boral Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a research note on Tuesday, January 6th. Finally, Citigroup began coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Compass Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $13.36.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.